MedTrace Logo

Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer

NCT04110769 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-07-20

No results posted yet for this study

Summary

The purpose of this study is to identify and apply biomarkers that can provide better information than previous imaging and blood tests when evaluating the response after neoadjuvant chemotherapy in pancreatic cancer patients who require neoadjuvant therapy before surgery.

Conditions

Interventions

DIAGNOSTIC_TEST

next generation sequencing

the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.

DIAGNOSTIC_TEST

following next generation sequencing

The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Song-Choel Kim, MD.PhD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110769 on ClinicalTrials.gov